CGEN 855 targets the FPRL1 GPCR.

Compugen signed a collaboration agreement with Merck KGaA, acting for its pharmaceutical division Merck Serono, covering CGEN-855, a Compugen-discovered peptide targeting the FPRL1 GPCR. The agreement covers additional research to be conducted by Compugen, and provides Merck Serono with an option to exclusively license the peptide for worldwide development and commercialization.

CGEN-855 was discovered using Compugen’s GPCR peptide ligands discovery platform.

Previous articleD-Finitive Cell Technologies to Help Sigma Expand Its Regenerative Medicine Offerings
Next articleSARS May Have Originated in Bats